Overview

This program offers a comprehensive exploration of advanced clear cell renal cell carcinoma (RCC) management, focusing on approved frontline combinations of immunotherapy and/or targeted therapy, insights into HIF2-alpha involvement in RCC pathogenesis, and strategies for managing treatment-related adverse events.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Identify the approved frontline combinations of immunotherapy and/or targeted therapy in advanced clear cell renal cell carcinoma and gain insights into the factors guiding the selection between these combinations for individual patients

2. Discuss the involvement of hypoxia-inducible factor-2 alpha (HIF2-alpha) in the pathogenesis of renal cell carcinoma (RCC) and the role of HIF2α inhibition in the management of metastatic disease

3. Distinguish between adverse events associated with immunotherapy and those related to targeted therapy, and comprehend the strategies for managing these adverse events in patients with RCC.